LISTING OF CLAIMS

The current listing of claims supersedes all previous listings of claims.

1 – 24 (Cancelled)

25. (Previously Presented) A pharmaceutical composition for topical administration comprising the following components in the indicated w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpyrrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase; 1.5% of guar gum; 1% of polyoxyethylenesorbitan monolaurate; 0.5% of polyoxyethylenesorbitan monooleate, and the necessary amount of water to 100%.

26. (Cancelled)

27. (Previously Presented) A pharmaceutical composition for topical administration comprising the following components in the indicated approximate w/w percentages: 0.5-1.5% of a lidocaine base; 0.5-1.5% of a prilocaine base; 0.5-8% of a tetracaine base; 10% of methylpyrrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase; 1.5% of guar gum; 1% of polyoxyethylenesorbitan monolaurate; 0.5% of polyoxyethylenesorbitan monooleate, and the necessary amount of water to 100%

28. (Previously Presented) A pharmaceutical composition for topical administration comprising:

(i) a therapeutically safe and effective amount of lidocaine or of a pharmaceutically acceptable salt thereof;

(ii) a therapeutically safe and effective amount of prilocaine or of a pharmaceutically acceptable salt thereof; and

(iii) a therapeutically safe and effective amount of tetracaine or of a pharmaceutically acceptable salt thereof,

wherein the pharmaceutical composition is administered without occlusion.

29. (Previously Presented) The pharmaceutical composition according to claim 28, further comprising water.

30. (Previously Presented) The pharmaceutical composition according to claim 28, wherein lidocaine or its salt on the one side, and prilocaine or its salt on the other side, form an eutectic mixture.

31. (Previously Presented) The pharmaceutical composition according to claim 28, wherein one or more of lidocaine or its salt is in an amount from about 0.5% to about 5% w/w, prilocaine or its salt is in an amount from about 0.5% to about 5% w/w, and tetracaine or its salt is in an amount from about 0.5% to about 8% w/w.

32. (Previously Presented) The pharmaceutical composition according to claim 31, wherein one or more of lidocaine or its salt is in an amount from about 0.5% to about 1.5% w/w, prilocaine or its salt is in an amount from about 0.5% to about 1.5% w/w, and tetracaine or its salt is in an amount from about 0.5% to about 8% w/w.

33. (Previously Presented) The pharmaceutical composition according to claim 32, wherein lidocaine or its salt is in an amount of about 1.5% w/w, and prilocaine or its salt is in an amount of about 1.5% w/w.

34. (Previously Presented) The pharmaceutical composition according to claim 32, wherein tetracaine or its salt is in an amount of about 4% w/w.

35. (Previously Presented) The pharmaceutical composition according to claim 32, wherein one or more of lidocaine or its salt is in an amount of about 1.5% w/w, prilocaine or its salt is in an amount of about 1.5% w/w, and tetracaine or its salt is in an amount of about 4% w/w.

36. (Previously Presented) The pharmaceutical composition according to claim 28, further comprising appropriate amounts of pharmaceutically acceptable excipients to constitute a topical formulation.

37. (Previously Presented) The pharmaceutical composition according to claim 36, wherein the excipients comprise one or a combination of two or more of at least one skin penetration enhancer, at least one spreading agent, at least one viscosity increasing agent, at least one surfactant, and at least one preservative.

38. (Previously Presented) The pharmaceutical composition according to claim 37, wherein the skin penetration enhancer includes one or both of methylpyrrolidone and dimethyl sulfoxide (DMSO).

39. (Previously Presented) The pharmaceutical composition according to claim 38, wherein methylpyrrolidone is in an amount from about 5% to about 20% w/w.

40. (Previously Presented) The pharmaceutical composition according to claim 39, wherein methylpyrrolidone is in an amount of about 10% w/w.

41. (Previously Presented) The pharmaceutical composition according to claim 38, wherein dimethyl sulfoxide is in an amount from about 0.5% to about 5% w/w.

42. (Previously Presented) The pharmaceutical composition according to claim 41, wherein dimethyl sulfoxide is in an amount of about 2% w/w.

43. (Previously Presented) The pharmaceutical composition according to claim 37, wherein the spreading agent is selected from hyaluronidases and derivatives of mucopolysaccharidases.

44. (Previously Presented) The pharmaceutical composition according to claim 37,

wherein the viscosity increasing agent is selected from guar gum and a carbomer.

45. (Previously Presented) The pharmaceutical composition according to claim 37, wherein the viscosity increasing agent is in an amount from about 0.5% to about 2% w/w.

46. (Previously Presented) The pharmaceutical composition according to claim 37, wherein the surfactant is a non-ionic surfactant.

47. (Previously Presented) The pharmaceutical composition according to claim 36, wherein the topical formulation is selected from the group consisting of lotions, creams, gels, sticks, sprays, ointments and pastes.

48. (Previously Presented) A method of use of a combination comprising lidocaine, prilocaine and tetracaine, any of which being as such or as a pharmaceutically acceptable salt, for the preparation of a topical anesthetic pharmaceutical composition; the method comprising: providing a combination of lidocaine, prilocaine and tetracaine themselves or as pharmaceutically acceptable salts thereof; and, administering the combination topically.